Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A real world, retrospective study to evaluate use of Secukinumab by describing demographic, clinical and treatment characteristics in patients with Ankylosing Spondylitis

Trial Profile

A real world, retrospective study to evaluate use of Secukinumab by describing demographic, clinical and treatment characteristics in patients with Ankylosing Spondylitis

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2018 According to a Novartis media release, data from this study will be presented at the Annual European Congress of Rheumatology (EULAR 2018).
    • 05 Jul 2017 New trial record
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top